According to a recent SEC filing, Director George Morrow has sold 40,000 shares of Neurocrine Biosciences Inc (NBIX, Financial) on March 14, 2024. The transaction was executed at a price of $139.42 per share, resulting in a total sale amount of $5,576,800.
Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases and disorders. The company's portfolio includes products for endometriosis, tardive dyskinesia, and Parkinson's disease, among other conditions.
Over the past year, George Morrow has sold a total of 40,000 shares of Neurocrine Biosciences Inc and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of insider sales, with 73 insider sells and no insider buys over the past year.
On the valuation front, Neurocrine Biosciences Inc's shares were trading at $139.42 on the day of the insider's recent sale, giving the company a market cap of $13.848 billion. The price-earnings ratio stands at 57.48, which is above the industry median of 22.61 but below the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 0.93, with a GF Value of $150.71, indicating that Neurocrine Biosciences Inc is fairly valued according to GuruFocus's intrinsic value estimate. The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
